The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Jonsson Comprehensive Cancer Center

ClinicalTrials.gov Identifier:

NCT01180907

First received: August 11, 2010

Last updated: July 27, 2012

Last verified: July 2012

History of Changes

Purpose

The purpose of the study is to determine whether positron emission tomography using the new imaging agent 18F-FAC can be used for imaging cancer and/or inflammation.

Condition
Cancer Inflammation


Study Type:	Observational
Official Title:	The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases: A Pilot Study

Resource links provided by NLM:

MedlinePlus related topics: Cancer

U.S. FDA Resources

Further study details as provided by Jonsson Comprehensive Cancer Center:


Enrollment:	10
Study Start Date:	November 2007
Primary Completion Date:	November 2011 (Final data collection date for primary outcome measure)

Groups/Cohorts
patients with cancer
patients with autoimmune diseases
healthy subjects

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

patients with cancer, autoimmune diseases and healthy subjects

Criteria

Inclusion Criteria:

> 18 years of age
women of childbearing potential will undergo a pregnancy test free of charge
patients with cancer or autoimmune diseases or healthy subjects

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01180907

Locations


United States, California
UCLA
Los Angeles, California, United States, 90095

Sponsors and Collaborators

Jonsson Comprehensive Cancer Center

Investigators


Principal Investigator:	Christiaan Schiepers, M.D. Ph.D	University of California, Los Angeles

More Information

No publications provided


Responsible Party:	Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:	NCT01180907 History of Changes
Other Study ID Numbers:	07-07-071, DE-PS02-08ER-08-01, CIRMNo. RT1-01126-1, 10-000269
Study First Received:	August 11, 2010
Last Updated:	July 27, 2012
Health Authority:	United States: Institutional Review Board

Keywords provided by Jonsson Comprehensive Cancer Center:


18F-FAC imaging cancer inflammation PET

Additional relevant MeSH terms:


Inflammation Pathologic Processes

ClinicalTrials.gov processed this record on February 27, 2015

To Top